|
US7056916B2
(en)
|
2002-11-15 |
2006-06-06 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Medicaments for the treatment of chronic obstructive pulmonary disease
|
|
GB0401334D0
(en)
|
2004-01-21 |
2004-02-25 |
Novartis Ag |
Organic compounds
|
|
ES2380370T3
(es)
*
|
2004-04-22 |
2012-05-11 |
Boehringer Ingelheim International Gmbh |
Combinaciones farmacológicas que contienen benzoxazina para el tratamiento de enfermedades de las vías respiratorias
|
|
DE102004019539A1
(de)
*
|
2004-04-22 |
2005-11-10 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue Arzneimittel zur Behandlung von Atemwegserkrankungen
|
|
JP2007537187A
(ja)
*
|
2004-05-13 |
2007-12-20 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
呼吸器疾患の治療においてβアゴニストとして使用するためのヒドロキシ置換ベンゾ縮合ヘテロ環化合物
|
|
DE102004024454A1
(de)
*
|
2004-05-14 |
2005-12-08 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue Enantiomerenreine Betaagonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
|
|
DE102004024451A1
(de)
*
|
2004-05-14 |
2005-12-22 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Pulverformulierungen für die Inhalation, die Enantiomerenreine Betaagonisten enthalten
|
|
DE102004024452A1
(de)
*
|
2004-05-14 |
2005-12-08 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Aerosolformulierung für die Inhalation von Betaagonisten
|
|
US7220742B2
(en)
|
2004-05-14 |
2007-05-22 |
Boehringer Ingelheim International Gmbh |
Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
|
|
US20050256115A1
(en)
*
|
2004-05-14 |
2005-11-17 |
Boehringer Ingelheim International Gmbh |
Aerosol formulation for the inhalation of beta-agonists
|
|
US7745621B2
(en)
|
2004-05-14 |
2010-06-29 |
Boehringer Ingelheim International Gmbh |
Long acting bronchodilators for the treatment of respiratory diseases
|
|
DE102004024453A1
(de)
*
|
2004-05-14 |
2006-01-05 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue langwirksame Bronchodilatoren zur Behandlung von Atemwegserkrankungen
|
|
GB0411056D0
(en)
|
2004-05-18 |
2004-06-23 |
Novartis Ag |
Organic compounds
|
|
DE102004045648A1
(de)
*
|
2004-09-21 |
2006-03-23 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue Betamimetika zur Behandlung von Atemwegserkrankungen
|
|
GT200500281A
(es)
|
2004-10-22 |
2006-04-24 |
Novartis Ag |
Compuestos organicos.
|
|
GB0424284D0
(en)
|
2004-11-02 |
2004-12-01 |
Novartis Ag |
Organic compounds
|
|
GB0426164D0
(en)
|
2004-11-29 |
2004-12-29 |
Novartis Ag |
Organic compounds
|
|
DE102005007654A1
(de)
*
|
2005-02-19 |
2006-08-24 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue langwirksame Betamimetika zur Behandlung von Atemwegserkrankungen
|
|
GB0507577D0
(en)
|
2005-04-14 |
2005-05-18 |
Novartis Ag |
Organic compounds
|
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
|
DE102005030733A1
(de)
*
|
2005-07-01 |
2007-01-04 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue Arzneimittelkombinationen zur Behandlung von Atemwegserkrankungen enthaltend langwirksame Beta-2-Agonisten und wenigstens einen weiteren Wirkstoff
|
|
BRPI0614290A2
(pt)
|
2005-08-08 |
2011-03-22 |
Argenta Discovery Ltd |
derivados de biciclo [ 2.2.1 ] hept-7-ilamina e seus usos
|
|
GB0516313D0
(en)
|
2005-08-08 |
2005-09-14 |
Argenta Discovery Ltd |
Azole derivatives and their uses
|
|
WO2007020227A1
(de)
*
|
2005-08-15 |
2007-02-22 |
Boehringer Ingelheim International Gmbh |
Verfahren zur herstellung von betamimetika
|
|
US20070086957A1
(en)
*
|
2005-10-10 |
2007-04-19 |
Thierry Bouyssou |
Combination of medicaments for the treatment of respiratory diseases
|
|
TWI389692B
(zh)
*
|
2005-10-10 |
2013-03-21 |
Boehringer Ingelheim Int |
用以吸入β-共效劑的氣溶膠調配物
|
|
KR20080049113A
(ko)
|
2005-10-21 |
2008-06-03 |
노파르티스 아게 |
Il-13에 대항한 인간 항체 및 치료적 용도
|
|
CA2627726A1
(en)
*
|
2005-11-09 |
2007-05-18 |
Boehringer Ingelheim International Gmbh |
Aerosolformulation for inhalation
|
|
GB0601951D0
(en)
|
2006-01-31 |
2006-03-15 |
Novartis Ag |
Organic compounds
|
|
EP1986644A1
(de)
*
|
2006-02-16 |
2008-11-05 |
Boehringer Ingelheim International GmbH |
Arzneimittelkombinationen zur behandlung von atemwegserkrankungen
|
|
PE20080142A1
(es)
|
2006-03-15 |
2008-04-14 |
Boehringer Ingelheim Int |
Beta-agonistas enantiomericamente puros y sus procedimientos de preparacion
|
|
CA2649215A1
(en)
|
2006-04-21 |
2007-11-01 |
Novartis Ag |
2,6,9-trisubstituted purine compounds as adenosine aza receptor modulators
|
|
JP2010500319A
(ja)
*
|
2006-08-07 |
2010-01-07 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
鏡像体上純粋な新規ベータアゴニスト、それらの製造方法及び医薬としてのそれらの使用
|
|
UY30542A1
(es)
*
|
2006-08-18 |
2008-03-31 |
Boehringer Ingelheim Int |
Formulacion de aerosol para la inhalacion de agonistas beta
|
|
UY30543A1
(es)
*
|
2006-08-18 |
2008-03-31 |
Boehringer Ingelheim Int |
Formulacion de aerosol para la inhalacion de beta- agonistas
|
|
KR20090073121A
(ko)
|
2006-09-29 |
2009-07-02 |
노파르티스 아게 |
Pi3k 지질 키나제 억제제로서의 피라졸로피리미딘
|
|
BRPI0718266A2
(pt)
|
2006-10-30 |
2014-01-07 |
Novartis Ag |
Compostos heterocíclicos como agentes anti-inflamatórios.
|
|
DK2104535T3
(da)
|
2007-01-10 |
2011-04-04 |
Irm Llc |
Forbindelser og sammensætninger som kanalaktiverende proteaseinhibitorer
|
|
ES2370952T3
(es)
*
|
2007-01-25 |
2011-12-26 |
Boehringer Ingelheim International Gmbh |
Procedimiento para la preparación de betamiméticos.
|
|
DE602008005140D1
(de)
|
2007-05-07 |
2011-04-07 |
Novartis Ag |
Organische verbindungen
|
|
CA2707857C
(en)
|
2007-12-10 |
2016-09-13 |
Novartis Ag |
Spirocyclic amiloride analogues
|
|
PT2231642E
(pt)
|
2008-01-11 |
2014-03-12 |
Novartis Ag |
Pirimidinas como inibidores de quinase
|
|
ES2535736T3
(es)
|
2008-06-10 |
2015-05-14 |
Novartis Ag |
Derivados de pirazina como bloqueadores de los canales de sodio epitelial
|
|
US8236786B2
(en)
|
2008-08-07 |
2012-08-07 |
Pulmagen Therapeutics (Inflammation) Limited |
Respiratory disease treatment
|
|
DK2379507T3
(da)
|
2008-12-30 |
2014-01-27 |
Pulmagen Therapeutics Inflammation Ltd |
Sulfonamidforbindelser til behandling af åndedrætsforstyrrelser
|
|
US20110281917A1
(en)
|
2009-01-29 |
2011-11-17 |
Darrin Stuart |
Substituted Benzimidazoles for the Treatment of Astrocytomas
|
|
WO2010150014A1
(en)
|
2009-06-24 |
2010-12-29 |
Pulmagen Therapeutics (Inflammation) Limited |
5r- 5 -deuterated glitazones for respiratory disease treatment
|
|
US8389526B2
(en)
|
2009-08-07 |
2013-03-05 |
Novartis Ag |
3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
|
|
WO2011018454A1
(en)
|
2009-08-12 |
2011-02-17 |
Novartis Ag |
Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation
|
|
IN2012DN01961A
(en:Method)
|
2009-08-17 |
2015-08-21 |
Intellikine Llc |
|
|
WO2011050325A1
(en)
|
2009-10-22 |
2011-04-28 |
Vertex Pharmaceuticals Incorporated |
Compositions for treatment of cystic fibrosis and other chronic diseases
|
|
GB0918923D0
(en)
|
2009-10-28 |
2009-12-16 |
Vantia Ltd |
Aminothiazole derivatives
|
|
GB0918922D0
(en)
|
2009-10-28 |
2009-12-16 |
Vantia Ltd |
Aminopyridine derivatives
|
|
GB0918924D0
(en)
|
2009-10-28 |
2009-12-16 |
Vantia Ltd |
Azaindole derivatives
|
|
WO2011098746A1
(en)
|
2010-02-09 |
2011-08-18 |
Pulmagen Therapeutics (Inflammation) Limited |
Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone
|
|
GB201002243D0
(en)
|
2010-02-10 |
2010-03-31 |
Argenta Therapeutics Ltd |
Respiratory disease treatment
|
|
GB201002224D0
(en)
|
2010-02-10 |
2010-03-31 |
Argenta Therapeutics Ltd |
Respiratory disease treatment
|
|
US8247436B2
(en)
|
2010-03-19 |
2012-08-21 |
Novartis Ag |
Pyridine and pyrazine derivative for the treatment of CF
|
|
WO2012034095A1
(en)
|
2010-09-09 |
2012-03-15 |
Irm Llc |
Compounds and compositions as trk inhibitors
|
|
UY33597A
(es)
|
2010-09-09 |
2012-04-30 |
Irm Llc |
Compuestos y composiciones como inhibidores de la trk
|
|
US8372845B2
(en)
|
2010-09-17 |
2013-02-12 |
Novartis Ag |
Pyrazine derivatives as enac blockers
|
|
JP6084926B2
(ja)
*
|
2010-09-21 |
2017-02-22 |
インテクリン・セラピユーテイクス・インコーポレイテツド |
抗糖尿病固体医薬組成物
|
|
WO2012107500A1
(en)
|
2011-02-10 |
2012-08-16 |
Novartis Ag |
[1, 2, 4] triazolo [4, 3 -b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
|
|
WO2012116237A2
(en)
|
2011-02-23 |
2012-08-30 |
Intellikine, Llc |
Heterocyclic compounds and uses thereof
|
|
WO2012116217A1
(en)
|
2011-02-25 |
2012-08-30 |
Irm Llc |
Compounds and compositions as trk inhibitors
|
|
US8883819B2
(en)
|
2011-09-01 |
2014-11-11 |
Irm Llc |
Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
|
|
US9062045B2
(en)
|
2011-09-15 |
2015-06-23 |
Novartis Ag |
Triazolopyridine compounds
|
|
JP6165733B2
(ja)
|
2011-09-16 |
2017-07-19 |
ノバルティス アーゲー |
N−置換ヘテロシクリルカルボキサミド類
|
|
CN103946221B
(zh)
|
2011-09-16 |
2016-08-03 |
诺华股份有限公司 |
用于治疗囊性纤维化的杂环化合物
|
|
WO2013038373A1
(en)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
Pyridine amide derivatives
|
|
WO2013038378A1
(en)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
Pyridine amide derivatives
|
|
WO2013038381A1
(en)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
Pyridine/pyrazine amide derivatives
|
|
WO2013078440A2
(en)
|
2011-11-23 |
2013-05-30 |
Intellikine, Llc |
Enhanced treatment regimens using mtor inhibitors
|
|
US8809340B2
(en)
|
2012-03-19 |
2014-08-19 |
Novartis Ag |
Crystalline form
|
|
MX371119B
(es)
|
2012-04-03 |
2020-01-17 |
Novartis Ag |
Productos de combinacion con los inhibidores de cinasa de tirosina y su uso.
|
|
WO2014056840A1
(en)
|
2012-10-09 |
2014-04-17 |
Boehringer Ingelheim International Gmbh |
Beta-2-adrenoceptor agonist for the treatment of cough
|
|
US9073921B2
(en)
|
2013-03-01 |
2015-07-07 |
Novartis Ag |
Salt forms of bicyclic heterocyclic derivatives
|
|
WO2014151147A1
(en)
|
2013-03-15 |
2014-09-25 |
Intellikine, Llc |
Combination of kinase inhibitors and uses thereof
|
|
TW201605450A
(zh)
|
2013-12-03 |
2016-02-16 |
諾華公司 |
Mdm2抑制劑與BRAF抑制劑之組合及其用途
|
|
US10004732B2
(en)
|
2014-04-24 |
2018-06-26 |
Novartis Ag |
Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
|
|
BR112016023967A2
(pt)
|
2014-04-24 |
2017-08-15 |
Novartis Ag |
derivados de pirazina como inibidores de fosfatidilinositol 3-cinase
|
|
WO2015162456A1
(en)
|
2014-04-24 |
2015-10-29 |
Novartis Ag |
Amino pyridine derivatives as phosphatidylinositol 3-kinase inhibitors
|
|
WO2016011658A1
(en)
|
2014-07-25 |
2016-01-28 |
Novartis Ag |
Combination therapy
|
|
MX373272B
(es)
|
2014-07-31 |
2020-04-16 |
Novartis Ag |
Terapia de combinacion.
|
|
WO2018108669A1
(en)
|
2016-12-12 |
2018-06-21 |
Boehringer Ingelheim International Gmbh |
Nintedanib for use in methods for the treatment of interstitial lung diseases by coadministration with olodaterol
|
|
WO2018114887A1
(en)
|
2016-12-20 |
2018-06-28 |
Laboratorios Lesvi, S.L. |
Improved process for the manufacture of r-6-hydroxy-8-[1-hydroxy-2-[2-(4-methoxyphenyl)-1,1-dimethylethylaminoethyl]-2h-1,4-benzoxazin-3(4h)-one hydrochloride
|
|
CN109096218B
(zh)
*
|
2018-08-06 |
2020-10-27 |
上海方予健康医药科技有限公司 |
盐酸奥达特罗晶型a及其制备方法
|
|
CN108997248B
(zh)
*
|
2018-08-06 |
2023-08-01 |
上海方予健康医药科技有限公司 |
盐酸奥达特罗晶型b及其制备方法
|
|
WO2020250116A1
(en)
|
2019-06-10 |
2020-12-17 |
Novartis Ag |
Pyridine and pyrazine derivative for the treatment of cf, copd, and bronchiectasis
|
|
JP2022547427A
(ja)
|
2019-08-28 |
2022-11-14 |
ノバルティス アーゲー |
置換1,3-フェニルヘテロアリール誘導体及び疾患の治療におけるその使用
|
|
US11304897B2
(en)
|
2020-06-09 |
2022-04-19 |
Anovent Pharmaceutical (U.S.), Llc |
Pharmaceutical formulation containing umeclidinium bromide and vilanterol trifenatate
|
|
US11331322B1
(en)
|
2021-09-15 |
2022-05-17 |
Santen Pharmaceutical Co., Ltd. |
Medicament for preventing and/or treating dry eye
|